Sai Parenteral's IPO Review
Sai Parenteral's IPO has been reviewed by 10 analysts, and the overall consensus is Avoid — carrying a score of 33. Out of the 10 analysts who have covered this IPO, 3 recommend subscribing while 7 advise caution or avoidance — reflecting a cautious view from the analyst community.
The issue is priced in the band of ₹372-392 per share, with a minimum application size of 38 shares (minimum investment of approximately ₹14,896 at the upper band). Subscription ran from 24 Mar 2026 to 27 Mar 2026. The issue size is ₹409 crore, entirely an offer for sale — the company receives none of the proceeds. Scroll down for the full analyst breakdown and analyst-wise verdicts.
Researched & reviewed by
Abhishek Vohera,
Founder, IPO Guru
Last updated
Figures sourced from the RHP, BSE & NSE
Analyst verdict & score
One score out of 100, aggregated from every analyst verdict tracked for this issue. How it's calculated
Higher consensus indicates broader analyst agreement.
Detailed review
What the analyst reports say, grouped by the question you're likely asking.
General review
Listing gains
Short-term strategy
Long-term strategy
How this is written: an AI-assisted summary of the 14 analyst reports listed below. It reports their views; IPO Guru does not make buy or sell recommendations.
Analyst reviews
Ordered by each analyst's track record over the past year; analysts still building one are listed last.
Latest IPO reviews
How analysts rated the most recent mainboard issues — and, where they have listed, how the call played out.
Frequently asked
Should I apply for Sai Parenteral's IPO?
The analyst consensus for Sai Parenteral's IPO tracked on this page is Avoid, with a score of 33/100. Out of 10 analysts who have reviewed this IPO, 3 recommend subscribing. IPO Guru does not make buy or sell recommendations. Read the individual analyst reports and consult a SEBI-registered advisor before investing.
What does the score of 33 mean for Sai Parenteral's IPO?
The score of 33 is an aggregate of all analyst ratings tracked for Sai Parenteral's IPO. A score in this range signals that most analysts are advising caution or outright avoidance. Read the individual analyst verdicts above for more context.
What was the actual listing price of Sai Parenteral's IPO?
Sai Parenteral's IPO listed on April 2, 2026 at ₹400, against the issue price of ₹392 — a gain of +2.04% (₹8 per share). View the full GMP history page for day-wise pre-listing trends.
What is the price band and lot size of Sai Parenteral's IPO?
Sai Parenteral's IPO was priced at ₹372-392 per share. The minimum lot size is 38 shares, making the minimum investment approximately ₹14,896 at the upper end of the price band. Subscription ran from 24 Mar 2026 to 27 Mar 2026.
Explore Sai Parenteral's IPO further
Analyst views are one input. Read them alongside the demand, the grey market and the filings before you decide.
It has listed — go back to the fundamentals.
Live grey market premium, Kostak and Subject to Sauda, with the day-wise trend.
Category-wise demand from QIB, NII and retail investors, updated through the day.
Check with your PAN whether shares were credited to your demat account.
A verdict is an opinion, not a guarantee.
IPO Guru collects analyst views, GMP, subscription and allotment for every Mainboard and SME issue. Weigh them together — and against the offer document — before you apply.
Disclaimer: Grey Market Premium (GMP) is for information purposes and is not a guarantee of listing price. Always consult your financial advisor before investing.
